title: Effect of sodium nitroprusside on complement activation induced by cardiopulmonary bypass: a clinical and experimental study.
abstract: Complement activation and leukocyte stimulation were prospectively studied during and after cardiopulmonary bypass in 16 children receiving sodium nitroprusside--a nitrovasodilator releasing nitric oxide--for vasodilation during the cooling and rewarming periods of extracorporeal circulation. Results were compared with those in 29 patients who were not treated with sodium nitroprusside during the operation. Patients treated with sodium nitroprusside had significantly less C3 conversion during cardiopulmonary bypass as measured by the ratio C3d/C3 (p <0.05) and significantly less C5a liberation immediately after cardiopulmonary bypass (p < 0.005) than patients not treated with sodium nitroprusside. C4 was not overtly consumed in our series. Leukocyte count during the rewarming period of cardiopulmonary bypass, but not leukocyte elastase release during cardiopulmonary bypass, was significantly reduced in patients treated with sodium nitroprusside (p <0.05). In vitro experiments were conducted to analyze the effect of sodium nitroprusside on complement hemolytic activity initiated by the classic and the alternate pathways and on zymosan-induced C3 conversion by the activation of the alternate pathway. The in vitro experiments clearly demonstrate inhibition of complement hemolytic activity by sodium nitroprusside in the sera tested. The 50% inhibitory concentration of sodium nitroprusside on the available complement hemolytic activity was less through the alternate pathway than through the classic one (4.2 +/- 0.8 mmol/L and 14.0 +/- 2.88 mmol/L, respectively). The decrease of complement hemolytic activity measured was dose-dependent and was enhanced by the sodium nitroprusside preincubation of the sera tested. This effect was related to the duration of preincubation. Sodium nitroprusside photodegradation (enhancing nitric oxide release) increased the anticomplementary effect of the drug, reducing the 50% inhibitory concentration on complement hemolytic activity to 0.24 to 0.02 mmol/L for the alternate pathway and 2.74 o 0.3 mmol/L for the classic pathway. the zymosan-induced C3 conversion was inhibited by sodium nitroprusside. Nitroglycerin and isosorbide dinitrate (other nitric oxide donors) had in vitro effects on complement hemolytic activity similar to those of nonphotodegraded sodium nitroprusside at similar concentrations (1 mmol/L). Our results suggest that sodium nitroprusside, both in vitro and in vivo, has an inhibiting effect on complement activation initiated by both classic and alternate pathways and that this effect is mediated by nitric oxide release from sodium nitroprusside. This is the first report on the anticomplementary effect of sodium nitroprusside by nitric oxide release.
authors.affiliation: Department of Pediatric Cardiology, Université Libre de Bruxelles, Brussels, Belgium.
authors.forename: M C
authors.initials: MC
authors.lastname: Seghaye
authors.forename: J
authors.initials: J
authors.lastname: Duchateau
authors.forename: R G
authors.initials: RG
authors.lastname: Grabitz
authors.forename: T
authors.initials: T
authors.lastname: Wolff
authors.forename: C
authors.initials: C
authors.lastname: Marcus
authors.forename: W
authors.initials: W
authors.lastname: Engelhardt
authors.forename: H
authors.initials: H
authors.lastname: Hörnchen
authors.forename: B J
authors.initials: BJ
authors.lastname: Messmer
authors.forename: G
authors.initials: G
authors.lastname: von Bernuth
mesh_terms: D002315:Cardiopulmonary Bypass; D002648:Child; D002675:Child, Preschool; D003167:Complement Activation / Q000187:drug effects*; D003176:Complement C3 / Q000032:analysis; D003181:Complement C4 / Q000032:analysis; D003170:Complement Pathway, Alternative / Q000187:drug effects; D003171:Complement Pathway, Classical / Q000187:drug effects; D006330:Heart Defects, Congenital / Q000503:physiopathology / Q000601:surgery; D006801:Humans; D007223:Infant; D007958:Leukocyte Count; D019272:Leukocyte Elastase; D009599:Nitroprusside / Q000494:pharmacology*; D010196:Pancreatic Elastase / Q000378:metabolism; D011446:Prospective Studies; D014665:Vasodilator Agents / Q000494:pharmacology*
chemical_list: D003176:Complement C3; D003181:Complement C4; D014665:Vasodilator Agents; D009599:Nitroprusside; D010196:Pancreatic Elastase; D019272:Leukocyte Elastase